Not a complete failure but seemingly not worth more than a two cent SP. HCV does not hide in reservoirs and trials have proven little. Those trials were mooted by BIT to move into US trials with DAAs. It never happened. Now they think that China will continue to use interferon based HCV treatments and 225 may help the success rate amongst the co-infected. I'm not convinced about this. Sofosbuvir is very cheap and approved in China these days. Other treatments are curing HCV in just two months. Interferon based regimes take a full year. The drug, along with Ribavirin, is universally hated for side effects.
Ann: Presentation of BIT225-009 HIV-1 Phase 2 Data, page-555
-
- There are more pages in this discussion • 484 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $7.664K | 403.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1202498 | 5 |
View Market Depth
| Last trade - 13.42pm 27/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |